ERBB2 and breast carcinoma: Having established the binding of HER2 to chromatin in two breast cancer cell lines, a modified rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) protocol was used to identify partners of HER2 at the chromatin [24].